LifeVantage (LFVN) Panoramica del titolo
LifeVantage Corporation si occupa dell'identificazione, della ricerca, dello sviluppo, della formulazione e della vendita a livello internazionale di attivatori nutrigenomici avanzati, integratori alimentari, nootropi, prodotti per la gestione del peso, pre e pro-biotici e prodotti per la cura della pelle e dei capelli. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 4/6 |
| Crescita futura | 0/6 |
| Prestazioni passate | 1/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 3/6 |
LFVN Community Fair Values
Create NarrativeSee what 45 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di LifeVantage Corporation
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$5.17 |
| Massimo di 52 settimane | US$15.00 |
| Minimo di 52 settimane | US$3.90 |
| Beta | 0.55 |
| Variazione di 1 mese | 18.85% |
| Variazione a 3 mesi | 2.78% |
| Variazione di 1 anno | -61.39% |
| Variazione a 3 anni | 14.89% |
| Variazione a 5 anni | -37.33% |
| Variazione dall'IPO | -78.90% |
Notizie e aggiornamenti recenti
Recent updates
LFVN: Share Repurchases And Reset Expectations Will Support Future Upside Potential
Analysts have trimmed their price target on LifeVantage by $7, reflecting updated views on the company’s fair value and earnings power following recent research. Analyst Commentary Analysts cutting the target price by $7 signals a reset in expectations around what they see as a fair value for LifeVantage, given recent research on the company’s earnings power and execution risks.LFVN: Share Repurchases And Portugal Expansion Will Support Future Upside Potential
Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, revenue trends, profit margins, and expected future P/E multiples. Analyst Commentary Analysts link the lower price target to updated views on discount rates, revenue trends, profit margins, and expected future P/E multiples, which together affect how much investors may be willing to pay for LifeVantage shares.LFVN: Share Repurchases And Margin Discipline Will Support Future Upside Potential
Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, long term revenue trends, profit margins, and future P/E expectations. Analyst Commentary Analysts cutting the price target by $7 are updating their framework for discount rates, long term revenue trends, profit margins, and future P/E expectations.LFVN: Share Repurchases And Stable Margins Will Support Future Upside Potential
Analysts have trimmed their $7.00 price target on LifeVantage, citing updated fair value, discount rate, revenue, margin, and future P/E assumptions that now point to a more measured risk and return profile for the stock. Analyst Commentary Analysts cutting their $7.00 price target are largely reacting to updated views on fair value, discount rate, revenue, margins, and future P/E assumptions, which together frame a more balanced outlook for LifeVantage.LFVN: Buybacks And Margin Improvement Will Support Future Upside Potential
Narrative Update on LifeVantage Analysts have lowered their price target on LifeVantage by $7, citing updated assumptions for the discount rate, revenue trajectory, profit margin and future P/E, which together indicate a more cautious valuation framework. Analyst Commentary Analysts describe the lower price target as a reset of expectations rather than a change in the core story, anchoring their work in updated views on discount rate, revenue trajectory, profit margin and future P/E.LFVN: Higher Future P/E And Buybacks Will Support Confident Upside Potential
Analysts have reduced their price target on LifeVantage from $14.50 to $8.00, citing updated assumptions for revenue trends, profit margins, and a slightly adjusted discount rate, even as they apply a somewhat higher future P/E multiple. Analyst Commentary Analysts cutting the price target to $8.00 are recalibrating how they see LifeVantage balancing execution risk with potential upside in its valuation.Investors Give LifeVantage Corporation (NASDAQ:LFVN) Shares A 26% Hiding
Unfortunately for some shareholders, the LifeVantage Corporation ( NASDAQ:LFVN ) share price has dived 26% in the last...LFVN: Gut Health Research Progress Will Support Confident Upside Potential
Analysts are keeping their price target for LifeVantage steady at US$14.50, indicating only very small adjustments in their discount rate and long term assumptions such as revenue growth, profit margin and future P/E that do not materially change their overall view. What's in the News LifeVantage announced new in vitro study results for its proprietary P84 formula, showing strong biological activity in cellular pathways linked to gut regulation, repair, and restoration across four gut cell types (Key Developments).LFVN: Gut Study Advances And Guidance Confidence Will Support Future Upside Potential
Analysts have kept their price target for LifeVantage unchanged at $14.50, reflecting only minor tweaks to assumptions around discount rate, revenue growth, profit margin and future P/E, rather than a shift in their overall view of the stock. What's in the News LifeVantage reported new in vitro study results for its proprietary P84 formula, showing strong biological activity in cellular pathways tied to gut regulation, repair, and restoration across four gut cell types, with all 14 analyzed peptides and proteins moving in the intended direction in a controlled, third party study (Key Developments).LFVN: Gut Study Progress Will Drive Future Upside Potential
Analysts have slightly adjusted their price target for LifeVantage to $14.50, reflecting small tweaks to assumptions around the discount rate, long term revenue growth, profit margin, and future P/E used in their valuation models. What's in the News LifeVantage reported new in vitro study results for its proprietary P84 formula, with all 14 analyzed gut-related peptides and proteins moving in the desired direction in a controlled, third-party study across four gut cell types (Key Developments).LFVN: Future Gut Health Research And Buybacks Will Drive Upside
Analysts have modestly raised their price target on LifeVantage to 14.50 dollars from 14.50 dollars, citing largely unchanged expectations for fair value, discount rate, revenue growth, profit margins, and future valuation multiples that together reinforce a stable outlook for the shares. What's in the News New in vitro study of LifeVantage's P84 gut health formula showed strong biological activity across 14 key gut peptides and proteins, with several biomarkers increasing well above the 20 to 30 percent threshold typically considered meaningful in controlled cellular research (Key Developments) Key P84 results included a 1,087 percent increase in gastrin releasing peptide, a 116 percent increase in trefoil factor 3 for gut lining repair, and a 100 percent increase in vasoactive intestinal peptide that helps calm overactive areas of the gut (Key Developments) LifeVantage plans next phase research using mRNA sequencing to study P84 in combination with its Protandim Nrf2 Synergizer and MindBody GLP 1 System formulas, deepening the scientific backing for its gut and cellular activation portfolio (Key Developments) LifeVantage reported it has repurchased a cumulative 5,068,960 shares, or 37.65 percent of its outstanding stock, for 43.27 million dollars under a buyback program initiated in 2017, including 44,364 shares in the most recent quarter (Key Developments) The company reiterated fiscal 2026 guidance, expecting full year revenue between 225 million and 240 million dollars and forecasting second half revenue to exceed the first half, supported by MindBody product seasonality and the LoveBiome acquisition (Key Developments) Valuation Changes Fair Value Estimate: unchanged at 14.50 dollars per share, indicating no material shift in the intrinsic value assessment.LFVN: Future Index Inclusion Will Drive Upside Potential
Analysts have modestly raised their price target on LifeVantage to approximately $14.50 per share, reflecting slightly updated assumptions for discount rates, long term revenue growth, and profitability, while maintaining a broadly unchanged fair value outlook. What's in the News New in vitro study of LifeVantage’s proprietary P84 gut health formula showed strong biological activity across 14 key gut peptides and proteins, with several markers, including GRP, TFF3, VIP, and OXM, demonstrating notably large increases in levels, supporting the scientific rationale behind the product portfolio expansion (company study announcement).LFVN: Share Repurchases and New Index Addition Will Drive Value
LifeVantage Analyst Price Target Revised Downward Amid Softer Growth Expectations Analysts have lowered their price target for LifeVantage from $18.00 to $14.50. They cite reduced projections for revenue growth and profit margins as key factors in their updated assessment.Lacklustre Performance Is Driving LifeVantage Corporation's (NASDAQ:LFVN) 28% Price Drop
Unfortunately for some shareholders, the LifeVantage Corporation ( NASDAQ:LFVN ) share price has dived 28% in the last...We Ran A Stock Scan For Earnings Growth And LifeVantage (NASDAQ:LFVN) Passed With Ease
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...It's Down 25% But LifeVantage Corporation (NASDAQ:LFVN) Could Be Riskier Than It Looks
LifeVantage Corporation ( NASDAQ:LFVN ) shareholders that were waiting for something to happen have been dealt a blow...LifeVantage (NASDAQ:LFVN) Will Pay A Dividend Of $0.045
The board of LifeVantage Corporation ( NASDAQ:LFVN ) has announced that it will pay a dividend on the 16th of...The LifeVantage Advantage: High Retention, High Returns
Summary LifeVantage leads in nutrigenomics, focusing on how nutrition impacts gene expression for optimal health. LifeVantage projections indicate a strong 26.6% EPS CAGR through 2027, driven by high-margin products, cost controls, and a shift toward long-term wellness-focused consultant strategies. The MindBody GLP-1 System now accounts for most of LFVN’s growth, with 85% of new users on monthly subscriptions, creating a reliable and recurring revenue stream. Shares trade at a discounted 15.6x forward P/E, below the staples sector median and peers like Nature’s Sunshine, offering valuation upside, alongside dividend yield and liquidity strength. Risks include heavy reliance on one product and retention uncertainty, as subscription fatigue, or competitive GLP-1 alternatives could weaken revenue durability and challenge the bullish case. Read the full article on Seeking AlphaShareholders Can Be Confident That LifeVantage's (NASDAQ:LFVN) Earnings Are High Quality
When companies post strong earnings, the stock generally performs well, just like LifeVantage Corporation's...What You Can Learn From LifeVantage Corporation's (NASDAQ:LFVN) P/E After Its 26% Share Price Crash
To the annoyance of some shareholders, LifeVantage Corporation ( NASDAQ:LFVN ) shares are down a considerable 26% in...
New Initiatives Will Drive MindBody GLP-1 System's Future Success
Expansion into international markets and enhanced supply chain capacity are expected to drive significant revenue growth and stabilize future sales.LifeVantage (NASDAQ:LFVN) Will Pay A Dividend Of $0.04
LifeVantage Corporation's ( NASDAQ:LFVN ) investors are due to receive a payment of $0.04 per share on 17th of March...LifeVantage Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
It's been a mediocre week for LifeVantage Corporation ( NASDAQ:LFVN ) shareholders, with the stock dropping 10% to...LifeVantage: Post-Earnings Sell-Off Provides Buying Opportunity
Summary LifeVantage Corporation's Q2 FY2025 results were boosted by the successful launch of the MindBody GLP-1 system. LFVN revenues jumped by more than 40% on a sequential basis, while free cash flow of $8.7 million represented a new multi-year high. However, elevated commissions and incentive expenses impacted profitability, thus resulting in a rather mediocre Adjusted EBITDA margin of 9.6%. While the current expense headwinds are expected to abate going into FY2026, I have lowered Adjusted EBITDA estimates and reduced my price target from $31 to $27. While investor disappointment is understandable, I consider the post-earnings sell-off a buying opportunity. That said, with the story being largely tied to the persistent success of a single blockbuster product, the investment thesis is not without risks. Read the full article on Seeking AlphaLifeVantage Corporation (NASDAQ:LFVN) Looks Just Right With A 33% Price Jump
Despite an already strong run, LifeVantage Corporation ( NASDAQ:LFVN ) shares have been powering on, with a gain of 33...What Is LifeVantage Corporation's (NASDAQ:LFVN) Share Price Doing?
LifeVantage Corporation ( NASDAQ:LFVN ), is not the largest company out there, but it led the NASDAQCM gainers with a...Market Participants Recognise LifeVantage Corporation's (NASDAQ:LFVN) Earnings Pushing Shares 31% Higher
LifeVantage Corporation ( NASDAQ:LFVN ) shares have continued their recent momentum with a 31% gain in the last month...LifeVantage (NASDAQ:LFVN) Will Be Hoping To Turn Its Returns On Capital Around
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...Rendimenti per gli azionisti
| LFVN | US Personal Products | US Mercato | |
|---|---|---|---|
| 7D | -3.2% | -5.1% | 1.1% |
| 1Y | -61.4% | -18.6% | 26.7% |
Ritorno vs Industria: LFVN ha avuto una performance inferiore rispetto al US Personal Products che ha registrato un rendimento -18.6 % nell'ultimo anno.
Rendimento vs Mercato: LFVN ha avuto una performance inferiore al mercato US che ha registrato un rendimento 26.7 % nell'ultimo anno.
Volatilità dei prezzi
| LFVN volatility | |
|---|---|
| LFVN Average Weekly Movement | 9.6% |
| Personal Products Industry Average Movement | 8.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: LFVN non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 10% ) di LFVN è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| n/a | 235 | Michael Beindorff | www.lifevantage.com |
LifeVantage Corporation si occupa dell'identificazione, della ricerca, dello sviluppo, della formulazione e della vendita a livello internazionale di attivatori nutrigenomici avanzati, integratori alimentari, nootropi, prodotti per la gestione del peso, pre e pro-biotici e prodotti per la cura della pelle e dei capelli. Offre Protandim, un integratore alimentare; LifeVantage Omega+, un integratore alimentare che combina gli acidi grassi DHA ed EPA Omega-3 e Omega-7 e la vitamina D3; LifeVantage ProBio, un integratore alimentare per supportare la salute dell'intestino; LifeVantage IC Bright, un integratore per supportare la salute degli occhi e del cervello, ridurre l'affaticamento e l'affaticamento degli occhi, supportare le funzioni cognitive e supportare i normali schemi del sonno; LifeVantage Daily Wellness, un integratore alimentare per rafforzare la salute del sistema immunitario; LifeVantage Rise AM e Reset PM System che fornisce all'organismo i giusti nutrienti; LifeVantage D3+, un integratore alimentare che fornisce vitamina D3 e K2, magnesio, calcio e altri oligominerali per sostenere un sistema immunitario equilibrato, ossa forti e salute cardiovascolare; PhysIQ Fat Burn per favorire la gestione del peso; PhysIQ Prebiotic è un integratore alimentare progettato per sostenere i batteri buoni dell'intestino e un microbioma sano; MindBody GLP-1 System, un integratore alimentare che combina due prodotti, MB Core e MB Enhance, progettati per sostenere la gestione del peso e il benessere attivando naturalmente il GLP-1 e bilanciando i segnali lungo l'asse intestino-cervello; Petandim for Dogs, un integratore per combattere lo stress ossidativo nei cani; e Axio, una miscela di bevande energetiche nootropiche. Fornisce anche prodotti per la cura della pelle anti-invecchiamento, come collagene liquido, detergenti per il viso, crema per gli occhi, crema idratante, protezione solare, lozioni perfezionatrici e creme per le mani, oltre a shampoo, balsami nutrienti e sieri per il cuoio capelluto con il marchio TrueScience.
LifeVantage Corporation Riepilogo dei fondamenti
| LFVN statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$64.59m |
| Utili (TTM) | US$5.75m |
| Ricavi(TTM) | US$195.32m |
LFVN è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| LFVN Conto economico (TTM) | |
|---|---|
| Ricavi | US$195.32m |
| Costo del fatturato | US$42.70m |
| Profitto lordo | US$152.62m |
| Altre spese | US$146.87m |
| Utili | US$5.75m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 0.46 |
| Margine lordo | 78.14% |
| Margine di profitto netto | 2.94% |
| Rapporto debito/patrimonio netto | 0% |
Come si è comportato LFVN nel lungo periodo?
Vedi performance storica e confrontoDividendi
LFVN paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di LFVN| LifeVantage date dei dividendi | |
|---|---|
| Data di stacco del dividendo | Jun 01 2026 |
| Data di pagamento dei dividendi | Jun 15 2026 |
| Giorni fino al dividendo Ex | 16 days |
| Giorni prima della data di pagamento dei dividendi | 30 days |
LFVN paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di LFVNAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/15 01:51 |
| Prezzo dell'azione a fine giornata | 2026/05/15 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/06/30 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
LifeVantage Corporation è coperta da 5 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Ilya Zubkov | Freedom Broker |
| Mitchell Pinheiro | Imperial Capital |
| Ryan Meyers | Lake Street Capital Markets, LLC |